JoVE Journal
Chemistry
Chemistry
Un abonnement à JoVE est nécessaire pour afficher ce contenu.
Chapitres
résumé
This protocol describes the synthesis and characterization of a trans-cyclooctene (TCO)-modified antibody and a 177Lu-labeled tetrazine (Tz) radioligand for pretargeted radioimmunotherapy (PRIT). In addition, it details the use of these two constructs for in vivo biodistribution and longitudinal therapy studies in a murine model of colorectal cancer.